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Recently we published data showing that 
under some circumstances the effect of 
protein kinase M zeta (PKMζ) inhibition 
in the amygdala on the expression of fear-
potentiated startle (FPS) is a function of 
when the drug was applied relative to when 
testing occurred (Parsons and Davis, 2011). 
We showed in three separate experiments 
that if memory is tested anywhere from 
10 to 15 days after infusion of the PKMζ 
inhibitor zeta-pseudosubstrate inhibitory 
peptide (ZIP) there was no evidence of 
memory impairment. However, there was 
a reliable impairment if testing took place 
a few hours or a few days after infusion of 
ZIP. A commentary was published by Nader 
(2011) critiquing several aspects of our 
findings and the conclusions drawn. Here, 
we respond to the criticism.
OlfactOry fear cOnditiOning and 
the amygdala
The medial and cortical nuclei of the amyg-
dala receive dense olfactory input from both 
the olfactory bulb and piriform cortex, but 
there is also olfactory input to lateral/basolat-
eral amygdala from the piriform and perirhi-
nal cortices (reviewed in Otto et al., 2000). 
Several studies have argued that it is the 
BLA, and not the medial/cortical amygdala, 
that is the critical site of amygdala plastic-
ity underlying odor-signaled fear learning. 
First, lesions of the BLA block olfactory fear 
conditioning (Cousens and Otto, 1998), as 
do lesions of the perirhinal cortex (Herzog 
and Otto, 1998) which provide the olfactory 
input into the BLA. Work from our lab found 
similar results in that an NMDA antagonist 
applied to the BLA blocked the acquisition 
of olfactory fear learning, but had no effect 
when infused into the medial nuclei (Walker 
et al., 2005). These results are consistent with 
prior studies showing that NMDA antago-
nists delivered to the BLA block the acquisi-
tion of fear memory whether the shock is 
signaled by a light (Miserendino et al., 1990) 
or noise (Campeau et al., 1992). Finally, 
olfactory fear conditioning has been shown 
to activate the mRNA for BDNF in the BLA, 
but not the medial nuclei (Rattiner et al., 
2004) which is also the case when a visual 
cue is used to signal shock (Rattiner et al., 
2004). Thus, just as is the case when visual or 
auditory cues are used to signal shock, olfac-
tory fear conditioning depends on plasticity 
within the BLA. Therefore, the results of our 
experiments studying the role of PKMζ on 
olfactory fear memory are very unlikely to be 
unique to the modality of the conditioned 
stimulus.
ZiP cOncentratiOn and infusiOn 
vOlume
The issue of whether we used a dose of ZIP 
(10 nmol/μL, 0.5 μl/side) that was inade-
quate to permanently disrupt fear memory 
is one that we think will ultimately need to 
be answered with data rather than specula-
tion. Nonetheless, it is an important issue 
to consider. Dr. Nader states that “The dose 
used by the authors was four times lower 
that used in 9 of 10 studies on the topic.” 
We are puzzled as to where the “9 of 10 
studies” claim comes from. At the time our 
manuscript was accepted into publication 
only one paper (Migues et al., 2010) had 
used a dose four times higher than what we 
used. There were two other papers employ-
ing amygdala infusions of ZIP, one of those 
used the same dose we did (Kwapis et al., 
2009) and the other (Serrano et al., 2008) 
used the same concentration, but twice the 
volume (i.e., twice the dose). We have no 
reason to believe that the concentration 
of ZIP we used was inadequate because it 
has been used successfully to disrupt mem-
ory in many other tasks (e.g., Pastalkova 
et al., 2006) and we replicated the work in 
several studies using this dose when test-
ing occurred 2 h or a few days after infu-
sion of ZIP (Serrano et al., 2008; Kwapis 
et al., 2009).
We believe the same argument applies 
to the potential impact of the volume of 
infusion. We infused 0.5 μL/hemisphere of 
ZIP, which we would estimate is the volume 
used in a vast majority of published works 
employing microinfusions into the rat 
amygdala. Other studies have used higher 
volumes of ZIP when infusions are made 
into a larger area like the dorsal hippocam-
pus (e.g., Pastalkova et al., 2006). To contend 
that our dose was inadequate by contrasting 
it to experiments where the same concen-
tration of ZIP is being infused into a large 
structure is not an appropriate comparison. 
Finally, it should also be pointed out that we 
directly replicated (our Figure 3B) the find-
ings of the previous paper (Migues et al., 
2010) that ZIP interfered with memory 
recall when tested for a second time at a 
10-day interval, using one-fourth of the 
dose. If our dose was inadequate, then why 
does ZIP block memory expression during 
the 10-day test under some circumstances?
is the memOry weaker fOr the 
lOng-term tests?
In his commentary, Dr. Nader selects out 
our Figure 3B and makes the conclusion 
that “the vast majority of observed changes 
in behavior are due to reduced perfor-
mance of the control groups (forgetting), 
as opposed to increased performance by the 
ZIP treated groups.” Performance during 
the 10-day test was lower, yet the ZIP treated 
rats tested only at 10 days still showed over 
twice as much potentiation compared the 
animals tested 1 day after infusion (48 vs. 
19%). We would also like to point to our 
Figure 2B where the levels of potentiation 
in the control group tested at 15 days dif-
fered very little from the 2-day group and 
the same pattern of data was observed, with 
ZIP rats tested at 15 days showing nearly 
twice as much fear as those tested at 2 days 
(46 vs. 26%). In fact, an ANOVA on these 
data using test interval and drug as between-
subjects factors found there was no effect 
of test time but a significant main effect of 
drug (F = 5.27, p < 0.05) and, most ger-
mane to our argument, a significant inter-
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area (Shema et al., 2007; their Figure 1A), 
alternative behavioral metrics were used 
(Pastalkova et al., 2006; their Figure 3C), or 
the animals were tested repeatedly (Migues 
et al., 2010; their Figure 1). Thus, we felt that 
the evidence that PKMζ supported the per-
manent storage of memory in the amygdala 
was weak and incomplete, and thus neces-
sitated further testing. It could very well be 
that this kinase may be involved in memory 
maintenance in other brain areas (e.g., insu-
lar cortex), in fact the data from studies of 
taste aversion are compelling (e.g., Shema 
et al., 2007, 2011).
Finally, Dr. Nader argues that “the authors 
used a task that that (sic) cannot differenti-
ate between storage and retrieval impair-
ment views of recovery from amnesia.” Let 
us assume this is the case. Then most, if not 
all, of the dozen or so tasks used in papers 
where ZIP disrupted memory after infusion 
into the amygdala or other brain areas must 
all suffer this same drawback. Yet, nearly all 
of these papers came to the conclusion that 
the ZIP-induced deficits were indicative of 
an impairment of memory storage. If we 
want to conclude that the paradigms used so 
far to study the effects of ZIP are inadequate, 
then what have we learned about the role of 
PKMζ in memory?
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this experiment, and it is possible that for 
this single experiment it would be difficult 
show a significant disruption in memory. 
However, we would argue that the group 
means in this experiment and the two other 
similar ones (our Figures 2b, and 3b), paint 
a very clear picture. In no case was there ever 
a hint of impairment in ZIP treated rats, so 
it made little sense to increase the power 
and lower the SE by doubling or tripling the 
number of subjects in these experiments.
recOvery frOm amnesia
Dr. Nader asserts that “the impairment 
induced by ZIP could be partial erasure of 
the memory” and that “increases in perfor-
mance might be mediated by incubation of 
that memory (increases in responding over 
time), new learning adding onto the resid-
ual memory.” While these are important 
considerations, we believe they are unlikely 
to be a factor in our study because there 
is little evidence of incubation over time 
in our experiments and a reminder shock 
does not lead to any recovery in ZIP treated 
rats which were impaired 2 days after infu-
sion (our supplementary Figure 1). If some 
residual trace existed in ZIP treated rats, the 
reminder shock should have lead to recov-
ery in those animals (Squire, 2006).
The experiments in our paper were not 
designed to provide a definitive answer as to 
the nature of the performance deficit after 
PKMζ inhibition. Instead they were designed 
to simply test if those deficits are observed 
long after infusion of ZIP into the amygdala. 
Too many of the prior published experi-
ments (e.g., Serrano et al., 2008) infused 
ZIP, tested memory a few hours and/or a 
few days later, and concluded that the drug 
had erased memory. Some of the published 
studies tested longer after ZIP infusion, 
but in some cases the deficits were weaker 
action (F = 6.17, p < 0.05). This indicates 
that the effect of ZIP on memory was quite 
large during the test shortly after infusion, 
but when memory was tested at later time 
points there was absolutely no difference.
Another factor important to consider 
is that the percent potentiation value is a 
relative measure. In our paper, the percent 
FPS values reported were computed by 
comparing the amplitude of startle in the 
presence of the odor vs. to the startle stimuli 
that occur between each odor presentation. 
However, what we often see when testing 
occurs at long intervals is that startle lev-
els on the startle alone trials increase once 
the conditioned stimulus comes on (e.g., 
Walker and Davis, 2002), and consequently 
those percentages are lower. An alternative 
way to assess the results is to compute the 
percent potentiation relative to the star-
tle stimuli presented during the test ses-
sion just before the odor is first presented 
(what we call “leaders”). We have done this 
for the three experiments where we tested 
long-term and those data are depicted in 
Figure 1. The ZIP groups are all showing 
greater than 100% potentiation, except for 
those rats tested 1 or 2 days later. And, once 
again we find the critical significant interac-
tion when computed in this way when we 
consider the 15 and 10-day results (F = 9.67, 
p < 0.01), showing again the effect of ZIP on 
memory depended on the time after infu-
sion memory was measured. Thus, we think 
the data indicates very little weakening of 
the memory over time.
statistical cOnsideratiOns
Dr. Nader states that in our Figure S2 that 
the “SE of their control group is so large 
that it is unclear if any impairment could be 
found significantly different statistically.” It 
is certainly the case that the SE is higher in 
Figure 1 | Percent fear-potentiated startle values relative to the baseline startle stimuli (“leaders”) for the three experiments (Parsons and Davis, 2011) 
where memory was tested long after infusion of ZiP into the BLA. ZIP disrupted the expression of memory when tested 2 (A) or 1 days (B) after infusion, but 
not at 10 (B), 12 (C), or 15 days (A).
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